<DOC>
	<DOCNO>NCT02424799</DOCNO>
	<brief_summary>This First Time Human ( FTIH ) study , perform three part , design investigate safety , local tolerability , pharmacokinetics pharmacodynamics single repeat topical application 2 strength GSK2646264 correspond placebo within subject , healthy adult subject ( Part A ) , subject cold urticaria ( CU , Part B ) subject chronic spontaneous urticaria ( CsU , Part C ) . The study also measure short term effect GSK2646264 number size weal subject CsU , healthy subject subject CU follow provocation test .</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability , Pharmacodynamics Pharmacokinetics GSK2646264</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<criteria>Inclusion criterion subject Parts A , B C Male female subject age least 18 year ( Yrs ) time sign informed consent . The upper age limit subject define specific inclusion criterion cohort . All subject must free scar skin marking ( e.g . tattoos piercings ) open wound ( e.g . scar skin marking ) define area body cream apply onto , unless opinion investigator compromise subject safety quality data . Able refrain exposure extend direct sunlight study period , screen ( SCR ) follow , especially area treatment study . Able refrain shave wax area study cream apply duration study SCR follow . Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication follow visit time period 5 terminal halflive postlast dose determine follow Part A study . Capable give write informed consent , include compliance requirement restriction list consent form . Willing , commit able return clinic visit complete studyrelated procedure . Able read , understand complete study related questionnaire . Inclusion criterion specific healthy subject ( Part A ) The subject age 18 55 yr age inclusive , time signing informed consent . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 19 30 kg per square meter ( m^2 ) ( inclusive ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator , consultation GSK Medical Monitor ( MM ) require , agree document find unlikely introduce additional risk factor interfere study procedure . Demonstration positive weal flare reaction ( &gt; =3 millimeter ( mm ) diameter relative negative control ) least one allergen battery allergen ( mixed grass pollen , Dermatophagoides pteronyssinus , birch pollen cat dander ) skin prick test SCR . Subjects must free past present benign malignant skin condition disease , unless opinion investigator compromise subject 's safety quality data . Nonsmokers subject tobacco smoke : smoke le 5 cigarette per day commits smoke tobacco duration inhouse stay , commit stable moderate use ( determined Investigator ) tobacco nicotinecontaining product , include nicotine patches/gum , course study , long patch interfere study procedure . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ; postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international unit [ MlU ] /milliliter [ mL ] estradiol &lt; 40 picogram ( pg ) /mL ( &lt; 147 picomoles/litre ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method describe wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Additional Inclusion criterion specific subject CU ( Part B ) Diagnosed CU six week confirm medical history positive cold stimulation test assess TEMPTest 4.0 prior first dose . The subject age 18 70 yr age inclusive , time signing informed consent . Body weight &gt; =50 kg BMI within range 19 35 kg/m^2 ( inclusive ) . Other diagnosis CU , subject comorbidities would introduce additional risk factor interfere study procedure , determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator , consultation GSK MM require , agree document find unlikely introduce additional risk factor interfere study procedure . In addition , follow criterion apply minimum 4 patient Part B : Demonstration positive weal flare reaction ( &gt; =3 mm relative negative control ) least one allergen battery allergen ( mixed grass pollen , Dermatophagoides pteronyssinus , birch pollen cat dander ) skin prick test SCR , Subjects must free past present benign malignant skin condition disease , specify condition require eligibility subject define specific inclusion criterion CU cohort unless opinion investigator compromise subject safety quality data . Nonsmokers subject tobacco smoker : smoke le 5 cigarette per day commits smoke tobacco duration inhouse stay , commit stable moderate use ( determined Investigator ) tobacco nicotinecontaining product , include nicotine patches/gum , course study , long patch interfere study procedure . Female subject must agree use one contraception method list protocol , 28 day SCR visit followup visit time period 5 terminal halflive postlast dose determine follow Part A study . Additional Inclusion criterion specific subject CsU ( Part C ) The subject age 18 70 yr age inclusive , time signing informed consent . Body weight &gt; =50 kg BMI within range 19 35 kg/m2 ( inclusive ) Subjects score &gt; 14 UAS7 questionnaire 410 weal observe defined area body include study . This area must include either arm , leg side torso 7 consecutive day SCR period , prior Day 1 visit . If subject complete 7 consecutive day UAS questionnaire prior dose Day 1 due exceptional circumstance , SCR period may extend subject complete 7 consecutive day UAS questionnaire . This discretion Investigator . No aetiology identify chronic urticaria drugrelated inducible urticaria determine history , physical examination laboratory study . Subjects must free past present benign malignant skin condition disease , specify condition require eligibility subject define specific inclusion criterion CsU cohort unless opinion investigator compromise subject safety quality data . Other diagnosis CsU subject comorbidities would introduce additional risk factor interfere study procedure , determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator , consultation GSK MM require , agree document find unlikely introduce additional risk factor interfere study procedure . Female subject must agree use one contraception method 28 day SCR visit list protocol followup visit time period 5 terminal halflive postlast dose determine follow Part A study . All Cohorts Exclusion Criteria Thyroid stimulate hormone level outside normal range . Subjects history Graves disease . Subjects history thyroid cancer . Unable unwilling avoid use topical creams/lotions sit medication apply . Washing soap water permit . Based average correct QT interval heart rate ( Fridericia 's ) [ QTcF ] value triplicate ECGs obtain brief recording period : QTcF &gt; 450 msec ; QTcF &gt; 480 millisecond ( msec ) subject Bundle Branch Block . Alanine aminotransferase , alkaline phosphatase bilirubin â‰¥ 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) previous history uncomplicated cholecystectomy . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . History sensitivity study medication , component thereof , history anaphylaxis history drug allergy , opinion investigator GSK MM , contraindicate participation . Unable refrain vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 half life ( whichever longer ) prior SCR visit completion followup assessment , unless opinion Investigator , consultation GSK MM require , medication interfere study procedure compromise subject safety . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month SCR . A positive test HIV antibody . Lactating female . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day Use topical steroid calcinurin inhibitor prohibit study SCR follow . Exclusion related prior drug treatment : Intake oral corticosteroid within 7 day &gt; 10 milligram ( mg ) per day prior first SCR visit ; Use depot corticosteroid within 7 day prior first SCR visit ; Subjects take anticoagulant ( e.g . warfarin ) must warfarin within 21 day prior SCR . Subjects psoralen combine ultraviolet A ( PUVA ) treatment must use PUVA treatment within 21 day prior SCR . Subjects work Sponsor , CRO , one study centre . Country Specific Exclusion criterion Germany applies Part A , Part B Part C. Subjects live detention court order regulatory action , see Â§40 subsection 1 sentence 3 . 4 AMG . ( Arzneimittelgesetz ) . Additional Exclusion Part A Healthy Subjects Use H1 antihistamine within 3 day prior first SCR visit Additional Exclusion Part B CU Subjects Exclusion relate prior drug treatment : Use Zaditen ( Ketotifen ) within 14 day prior first SCR visit ; Use Doxepin AZU tricyclic antidepressant antihistaminergic property within 14 day prior first SCR visit ; Use H2 antihistamine within 7 day prior first SCR visit ; Use H1 antihistamine within 7 day prior first SCR visit ; Use monteleukast leukotriene antagonist within 7 day prior first SCR visit ; Use biologicals include omalizumab within 5 month prior first SCR visit . Additional Exclusion Part C CsUpatients Exclusion relate prior drug treatment : Intake cyclosporin within 10 day prior first SCR visit ; Intake immunosuppressant drug within 28 day first SCR visit ; Use monteleukast leukotriene antagonist within 7 day prior first SCR visit ; Use Dapsone within 7 day prior first SCR visit ; Use Zaditen ( Ketotifen ) within 14 day prior first SCR visit ; Use Doxepin AZU tricyclic antidepressant antihistaminergic property within 14 day prior first SCR visit ; Use H2 antihistamine within 7 day prior first SCR visit ; Use biologicals include omalizumab within 5 month prior first SCR visit ; Use H1 antihistamine license dose within 3 day prior first SCR visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Urticaria</keyword>
	<keyword>SYK Inhibitor</keyword>
</DOC>